Poolbeg Pharma PLC Immunomodulator I Patent Opposition Withdrawal (8374M)
19 Septiembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 8374M
Poolbeg Pharma PLC
19 September 2023
Poolbeg Pharma plc
Immunomodulator I Patent Opposition to be Withdrawn
Important step in continued protection of Poolbeg's patent
family
19 September 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that the opposition to one of its European patents
(Immunomodulator I) that was previously filed by a third party is
to be withdrawn.
In the pharmaceutical industry it is not unusual for patents to
be challenged. The Immunomodulator I European patent was opposed by
a third party in September 2021. Further to engaging with the
opposing party, Poolbeg has reached an amicable conclusion in
relation to the patent dispute without any financial compensation
between the parties. This has resulted in the opposing party
agreeing to withdraw its opposition to the Immunomodulator I
European patent and agreeing not to challenge any of Poolbeg's
Immunomodulator I or Immunomodulator II patents in the future.
The Company will be communicating with the European Patent
Office ('EPO') regarding the necessity of continuing with the
scheduled hearing in November. Based on specialist advice received,
and the fact that the patent went through an extensive examination
process prior to being granted by the EPO, Poolbeg continues to
have full confidence in the validity and strength of the patent and
will defend its intellectual property to the extent required.
Poolbeg has a worldwide licence for POLB 001 for all uses in
humans and is developing a strong IP portfolio with patents in
place, including Immunomodulator I and Immunomodulator II, covering
the use of the class of p38 MAP kinase (mitogen-activated protein
kinase) inhibitors for the treatment of severe influenza and
hypercytokinaemia. The Company has also filed patent applications
to expand its IP around POLB 001 and the use of p38 MAP kinase
inhibitors in new disease areas, such as oncology. This enhances
the value and attractiveness of POLB 001 to potential pharma
partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, said: "The favourable resolution of the opposition filed
against our Immunomodulator I European patent is an important
outcome for us. We have full confidence in the strength and
validity of our patent portfolio and look forward to continuing to
expand our intellectual property and protecting our pipeline of
assets. We remain committed to addressing global unmet medical
needs by driving innovation in healthcare."
Footnote:
Immunomodulator I: Use of p38 MAPK inhibitors for the treatment
of severe influenza
Immunomodulator II: Use of p38 MAPK inhibitors in combination
with antiviral compounds for treatment of severe influenza, and the
use of p38 MAPK inhibitors, alone or in combination with an
antiviral agent, for the treatment of hypercytokinaemia
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic
syndrome related diseases.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFFIAAITLIV
(END) Dow Jones Newswires
September 19, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024